Search for: "Novo Nordisk, Inc."
Results 81 - 100
of 134
Sorted by Relevance
|
Sort by Date
14 Aug 2012, 11:14 pm
Novo Nordisk, A/S, 108 F.3d 1361, 1365 (Fed. [read post]
25 Jan 2022, 3:11 pm
There have already been several significant settlements that appear positioned for court approval in 2022, including Twitter ($809.5 million); Teva Pharmaceutical Industries ($420 million); Luckin Coffee ($175 million); Granite Construction ($129 million); Novo Nordisk A/S ($100 million); Stamps.com ($100 million) and NCI Building Systems, Inc. ($100 million). [read post]
9 Mar 2022, 2:06 pm
In addition to these settlements that have final court approval hearings already scheduled in 2022, there are a number of other large pending settlements that do not yet have court hearings scheduled, including the $809.5 million Twitter settlement; the $100 million Novo Nordisk settlement; and the $100 million NCI Building Systems case. [read post]
5 Mar 2024, 10:55 am
., Novo Nordisk, and Purdue Pharmaceuticals. [read post]
7 Aug 2012, 11:45 pm
Novo Nordisk A/S, 566 U.S. __, 132 S. [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
28 Jul 2013, 9:29 am
Some of the other diabetes drugs being investigated include Bydureon and Onglyza, sold by Bristol-Myers Squibb; AstraZeneca and Victoza from Novo Nordisk; Tradjenta from Eli Lilly and Boehringer Ingelheim; and Nesina from Takeda. [read post]
27 May 2010, 3:20 am
(Patent Docs) PrandiMet (Repaglinide and Metformin) – US: Infringement of patent following Paragraph IV certification: Novo Nordisk Inc. et al. v. [read post]
17 Apr 2012, 5:55 pm
Novo Nordisk A/S that “[a] generic manufacturer may employ the counterclaim provision to force correction of a use code that inaccurately describes the brand’s patent as covering a particular method of using a drug. [read post]
1 Dec 2011, 6:25 am
Novo Nordisk A/S. [read post]
7 Dec 2011, 7:12 am
Novo Nordisk, which was also argued Monday. [read post]
28 Feb 2023, 12:22 pm
During 2022, the Bernstein Litowitz firm was lead or co-lead counsel in cases with settlements over $100 million: the Luckin Coffee settlement ($175 million) and the Novo Nordisk settlement ($100 million). [read post]
24 Aug 2011, 12:33 am
The lobbying push for a PTE (FDA Law Blog) US: Generics fees: A fantastic opportunity (profitability through simplicity) USPTO announces agenda for next BCP customer partnership meeting (Patent Docs) US: GOP candidates unified in opposition to embryonic cell research (Patent Docs) US: District Court Massachusetts: Method of detecting fetal down syndrome passes muster under Bilski‘s machine-or-transformation test: PerkinElmer, Inc., et. al. v. [read post]
14 Oct 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb) Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no… [read post]
17 Feb 2012, 11:53 am
Quicken Loans, Inc. [read post]
27 Feb 2009, 5:00 am
Teva Parenteral Medicines Inc. et al. [read post]
24 Mar 2011, 12:53 pm
Novo Nordisk A/SDocket: 10-844Issue(s): Whether the counterclaim provision of the Hatch-Waxman Act applies when (1) there is “an approved method of using the drug” that “the patent does not claim,” and (2) the brand submits “patent information” to the FDA that misstates the patent's scope, requiring “correct[ion]. [read post]
11 Dec 2013, 7:55 pm
See Novo Nordisk A/S v. [read post]
22 Oct 2015, 8:42 am
IMS Health, Inc., 131 S. [read post]
